explore -WSS

explore

author：explore 2025-09-27 21:14:43 - browse：31454

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： What American doctors can learn from their Israeli counterparts

entertainment

WSS

The 10 drugs up first for Medicare price negotiation

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Crinetics acromegaly drug succeeds in late

Humana sues Biden admin over Medicare Advantage audit rule

Cholera vaccine supplies dangerously low, outbreaks surging

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

explore

explore

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

Medicare isn't yet testing food as medicine

BioMarin wins approval for gene therapy to treat hemophilia A

Crinetics acromegaly drug succeeds in late

Guidelines to prevent youth baseball injuries need more muscle

Using force crossed my mind when examining a defiant young patient

Novavax promises a turnaround & Lilly roils the obesity market

Virtual repurposing can help discover new uses for existing drugs

Malaria cases in Florida and Texas: Here’s what you need to know

Doctor of U.S. President Joe Biden says he is fit for duty

leisure time

Medicare Advantage isn’t working — for anyone

Using force crossed my mind when examining a defiant young patient

ALS advocates say criticism of new drugs misses bigger picture

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Ethical issues complicate the benefits of medical crowdfunding

focus

explore

entertainment

Wikipedia